Literature DB >> 7248139

Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine 10,11-epoxide in epileptic patients.

J J MacKichan, P K Duffner, M E Cohen.   

Abstract

1. The relationships between saliva, free and total plasma concentrations of carbamazepine (CBZ) and carbamazepine 10,11-epoxide (CBZ-EP) were studied in 24 chronically medicated epileptic patients. Four patients were taking CBZ alone, while 20 were taking one or more additional anticonvulsant drugs. 2. The free fraction of CBZ in plasma ranged from 0.19 to 0.33 (mean 0.24) while the saliva:plasma (S:P) concentration ratios ranged from 0.20 to 0.35 (mean 0.27). The free fraction of CBZ-EP in plasma ranged from 0.16 to 0.50 (mean 0.32), while the S:P ratios ranged from 0.14 to 0.70 (mean, 0.43). The plasma protein binding and S:P ratios of these compounds appeared to be independent of age, sampling time and concurrently administered anticonvulsant drugs. 3. Significant linear relationships between saliva and total plasma concentrations and between saliva and free plasma concentrations were observed for both compounds (P less than 0.001). However, salivary concentrations of CBZ and CBZ-EP were significantly more reliable as predictors of their respective free plasma concentrations than of their respective total plasma concentrations (P less than 0.01). 4. It is concluded that measurement of CBZ and CBZ-EP in the saliva of chronically medicated epileptic patients provides a more reliable estimate of the pharmacodynamically active, free concentrations of these compounds in plasma.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7248139      PMCID: PMC1401743          DOI: 10.1111/j.1365-2125.1981.tb01851.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  22 in total

1.  Anticonvulsant level in saliva, serum, and cerebrospinal fluid.

Authors:  A S Troupin; P Friel
Journal:  Epilepsia       Date:  1975-06       Impact factor: 5.864

2.  Carbamazepine: biotransformation.

Authors:  A Frigerio; P L Morselli
Journal:  Adv Neurol       Date:  1975

3.  Carbamazepine: absorption, distribution, and excretion.

Authors:  P L Morselli
Journal:  Adv Neurol       Date:  1975

4.  Studies on plasma protein binding of carbamazepine.

Authors:  E Di Salle; G M Pacifici; P L Morselli
Journal:  Pharmacol Res Commun       Date:  1974-04

Review 5.  The binding of drugs by plasma proteins.

Authors:  M C Meyer; D E Guttman
Journal:  J Pharm Sci       Date:  1968-06       Impact factor: 3.534

6.  Influence of phenobarbital and diphenylhydantoin on plasma carbamazepine levels in patients with epilepsy.

Authors:  J Christiansen; M Dam
Journal:  Acta Neurol Scand       Date:  1973       Impact factor: 3.209

7.  Carbamazepine for epilepsy. A controlled prospective evaluation.

Authors:  J J Cereghino; J T Brock; J C Van Meter; J K Penry; L D Smith; B G White
Journal:  Neurology       Date:  1974-05       Impact factor: 9.910

8.  Physicochemical and biochemical aspects of pharmacology.

Authors:  B B Brodie
Journal:  JAMA       Date:  1967-11-13       Impact factor: 56.272

9.  Kinetics of carbamazepine and its 10,11-epoxide metabolite in children.

Authors:  A Rane; B Höjer; J T Wilson
Journal:  Clin Pharmacol Ther       Date:  1976-03       Impact factor: 6.875

10.  Plasma protein binding of carbamazepine.

Authors:  W D Hooper; D K Dubetz; F Bochner; L M Cotter; G A Smith; M J Eadie; J H Tyrer
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

View more
  17 in total

Review 1.  Therapeutic drug monitoring in saliva. An update.

Authors:  R K Drobitch; C K Svensson
Journal:  Clin Pharmacokinet       Date:  1992-11       Impact factor: 6.447

Review 2.  Feasibility of Using Oral Fluid for Therapeutic Drug Monitoring of Antiepileptic Drugs.

Authors:  Morgan Patrick; Samuel Parmiter; Sherif Hanafy Mahmoud
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-03       Impact factor: 2.441

Review 3.  Pharmacokinetics and Pharmacogenetics of Carbamazepine in Children.

Authors:  Natasa Djordjevic; Slobodan M Jankovic; Jasmina R Milovanovic
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

4.  The effects of age on carbamazepine pharmacokinetics and adverse effects.

Authors:  N Hockings; A Pall; J Moody; A V Davidson; D L Davidson
Journal:  Br J Clin Pharmacol       Date:  1986-12       Impact factor: 4.335

5.  A descriptive systematic review of salivary therapeutic drug monitoring in neonates and infants.

Authors:  Laura Hutchinson; Marlene Sinclair; Bernadette Reid; Kathryn Burnett; Bridgeen Callan
Journal:  Br J Clin Pharmacol       Date:  2018-03-25       Impact factor: 4.335

Review 6.  Anticonvulsant drugs. An update.

Authors:  M J Eadie
Journal:  Drugs       Date:  1984-04       Impact factor: 9.546

7.  Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone co-medication.

Authors:  R Riva; M Contin; F Albani; E Perucca; G Procaccianti; A Baruzzi
Journal:  Clin Pharmacokinet       Date:  1985 Nov-Dec       Impact factor: 6.447

Review 8.  Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. An update.

Authors:  L Bertilsson; T Tomson
Journal:  Clin Pharmacokinet       Date:  1986 May-Jun       Impact factor: 6.447

Review 9.  Free drug concentration monitoring in clinical practice. Rationale and current status.

Authors:  C K Svensson; M N Woodruff; J G Baxter; D Lalka
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

10.  Carbamazepine 10, 11 epoxide concentrations in epileptics on carbamazepine alone and in combination with other anticonvulsants.

Authors:  M J Brodie; G Forrest; W G Rapeport
Journal:  Br J Clin Pharmacol       Date:  1983-12       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.